Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
ABBV•Genmab and AbbVie said their epcoritamab and R-CHOP combination reduced the risk of disease progression or death by 51% in a late-stage study of newly diagnosed diffuse large B-cell lymphoma patients.
1. Study results
The companies said the combination reduced the risk of disease progression or death by 51% compared with R-CHOP alone. They said the trial was the first late-stage study of a bispecific antibody combination to significantly improve progression-free survival in first-line DLBCL. The safety profile was generally consistent with the known profiles of epcoritamab and R-CHOP; epcoritamab is not yet approved for patients newly diagnosed with the disease.
